Cargando…

Molecular mechanisms in multiple myeloma drug resistance

Multiple myeloma (MM) is predominantly an incurable malignancy despite high-dose chemotherapy, autologous stem cell transplant and novel agents. MM is a genetically heterogeneous disease and the complexity increases as the disease progresses to a more aggressive stage. MM arises from a plasma cell,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nikesitch, Nicholas, Ling, Silvia C W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752637/ https://www.ncbi.nlm.nih.gov/pubmed/26598624 http://dx.doi.org/10.1136/jclinpath-2015-203414

Ejemplares similares

Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance
por: Nikesitch, Nicholas, et al.
Publicado: (2018)

The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma
por: Nikesitch, Nicholas, et al.
Publicado: (2021)

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms
por: Abdi, Jahangir, et al.
Publicado: (2013)

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
por: Yang, Wen-Chi, et al.
Publicado: (2015)

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response
por: Nikesitch, N, et al.
Publicado: (2016)

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms
por: Abdi, Jahangir, et al.
Publicado: (2013)

Autophagy: A New Mechanism of Prosurvival and Drug Resistance in Multiple Myeloma
por: Desantis, V., et al.
Publicado: (2018)

Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
por: Davis, Lorraine N., et al.
Publicado: (2021)

Role of micro-RNAs in drug resistance of multiple myeloma
por: Abdi, Jahangir, et al.
Publicado: (2016)

Chromosomal instability and acquired drug resistance in multiple myeloma
por: Wang, Wang, et al.
Publicado: (2017)

Multiple Myeloma: Available Therapies and Causes of Drug Resistance
por: Pinto, Vanessa, et al.
Publicado: (2020)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma
por: Chen, Lucia Y., et al.
Publicado: (2022)

Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance
por: Mejia Saldarriaga, Mateo, et al.
Publicado: (2022)

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
por: Vo, Josh N., et al.
Publicado: (2022)

Microenvironment drug resistance in multiple myeloma: emerging new players
por: Di Marzo, Lucia, et al.
Publicado: (2016)

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma
por: Issa, Mark E., et al.
Publicado: (2017)

Overcoming drug resistance by targeting protein homeostasis in multiple myeloma
por: Moscvin, Maria, et al.
Publicado: (2021)

Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma
por: Herrero, Ana B., et al.
Publicado: (2016)

Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2022)

Cancer drug resistance in multiple myeloma
por: Uckun, Fatih M.
Publicado: (2022)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

The molecular pathogenesis of multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2020)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
por: Franssen, Laurens E., et al.
Publicado: (2020)

Role of epigenetics-microRNA axis in drug resistance of multiple myeloma
por: Rastgoo, Nasrin, et al.
Publicado: (2017)

Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma
por: Ria, Roberto, et al.
Publicado: (2020)

Looking into Endoplasmic Reticulum Stress: The Key to Drug-Resistance of Multiple Myeloma?
por: Wang, Guangqi, et al.
Publicado: (2022)

miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance
por: Tavakoli Pirzaman, Ali, et al.
Publicado: (2023)

Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy
por: Costacurta, Matteo, et al.
Publicado: (2021)

Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma
por: Comerford, Claire, et al.
Publicado: (2022)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

P841: MOLECULAR MECHANISMS OF RESISTANCE TO IMMUNOMODULATORS IN MULTIPLE MYELOMA: AN IN VITRO STUDY
por: Alves, Raquel, et al.
Publicado: (2023)

Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options
por: van Andel, Harmen, et al.
Publicado: (2019)

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
por: Franqui-Machin, Reinaldo, et al.
Publicado: (2015)

Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma
por: Allegra, Alessandro, et al.
Publicado: (2021)

Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
por: Innao, Vanessa, et al.
Publicado: (2021)

Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma
por: Bashiri, Hamed, et al.
Publicado: (2023)

Molecularly Targeted Therapies in Multiple Myeloma
por: de la Puente, Pilar, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_q0i9pikqmi44m47fn0krkuv4ck